{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:36Z","timestamp":1772119536998,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Higher on-treatment levels of low-density lipoprotein cholesterol in statin-treated patients were reportedly associated with the occurrence of neoatherosclerosis after drug-eluting stent (DES) implantation. We aimed to investigate the impact of alirocumab added to high-intensity statin therapy on neoatherosclerosis formation among patients with acute myocardial infarction (AMI) treated with DES. This was a pre-specified substudy of the PACMAN-AMI trial, a randomized, double-blind trial comparing alirocumab versus placebo added to high-intensity statin therapy in AMI patients. The present study included patients undergoing optical coherence tomography assessment of DES in the culprit lesion at one year. The frequency of neoatherosclerosis, neointimal thickness, and strut malapposition were compared between treatment groups. Among 191 patients (95 with alirocumab and 96 with placebo), neoatherosclerosis was observed in 13 patients (6.8%) at one year. There was no significant difference in the frequency of neoatherosclerosis between treatment groups (alirocumab 4.2% vs. placebo 9.4%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.25). Among 11 patients with lipid-laden neointima, minimal fibrous cap thickness was greater in the alirocumab group than in the placebo group (217.5\u2009\u00b1\u2009122.5 vs. 87.8\u2009\u00b1\u200949.1\u00a0\u03bcm,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02). Neointimal thickness (136.2\u2009\u00b1\u200971.1 vs. 151.4\u2009\u00b1\u2009101.4\u00a0\u03bcm,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.45) and the frequency of malapposed struts (0.94 vs. 0.53%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.27) were comparable between treatment groups. Among AMI patients treated with DES, there was no significant impact of alirocumab on the frequency of neoatherosclerosis and vessel healing at one year. The observed numerical difference and the finding of more stable neoatheroma in the alirocumab group need further investigation in larger studies with extended follow-up.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Alirocumab was associated with a numerically favourable, though not statistically significant, reduction in neoatherosclerosis at 1 year in AMI culprit lesions treated with newer-generation DES.<\/jats:p>","DOI":"10.1007\/s10554-025-03472-0","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:16:08Z","timestamp":1755497768000},"page":"1739-1748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial"],"prefix":"10.1007","volume":"41","author":[{"given":"Ryota","family":"Kakizaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos C.","family":"Koskinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Shibutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Losdat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio G.","family":"Biccir\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas D.","family":"H\u00e4ner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"L\u00f8nborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan F.","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna S.","family":"Ondracek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Spirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George C. M.","family":"Siontis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Engstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene M.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"R\u00e4ber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"10190","key":"3472_CR1","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(19)30474-X","volume":"22","author":"R Piccolo","year":"2019","unstructured":"Piccolo R, Bonaa KH, Efthimiou O, Varenne O, Baldo A et al (2019) Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet Jun 22(10190):2503\u20132510. https:\/\/doi.org\/10.1016\/S0140-6736(19)30474-X","journal-title":"Lancet Jun"},{"issue":"9","key":"3472_CR2","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.amjcard.2014.07.065","volume":"1","author":"JM Lee","year":"2014","unstructured":"Lee JM, Park KW, Han JK, Yang HM, Kang HJ et al (2014) Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the multicenter prospective EXCELLENT and RESOLUTE-Korea Registries). Am J Cardiol Nov 1(9):1329\u20131338. https:\/\/doi.org\/10.1016\/j.amjcard.2014.07.065","journal-title":"Am J Cardiol Nov"},{"issue":"9851","key":"3472_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/S0140-6736(12)61336-1","volume":"20","author":"E Camenzind","year":"2012","unstructured":"Camenzind E, Wijns W, Mauri L, Kurowski V, Parikh K et al (2012) Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet Oct 20(9851):1396\u20131405. https:\/\/doi.org\/10.1016\/S0140-6736(12)61336-1","journal-title":"Lancet Oct"},{"issue":"17","key":"3472_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jcin.2019.04.046","volume":"9","author":"C Zanchin","year":"2019","unstructured":"Zanchin C, Ueki Y, Zanchin T, Haner J, Otsuka T et al (2019) Everolimus-Eluting biodegradable polymer versus Everolimus-Eluting durable polymer stent for coronary revascularization in routine clinical practice. JACC Cardiovasc Interv Sep 9(17):1665\u20131675. https:\/\/doi.org\/10.1016\/j.jcin.2019.04.046","journal-title":"JACC Cardiovasc Interv Sep"},{"issue":"1","key":"3472_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jacc.2009.08.032","volume":"29","author":"M Takano","year":"2009","unstructured":"Takano M, Yamamoto M, Inami S, Murakami D, Ohba T et al (2009) Appearance of lipid-laden intima and neovascularization after implantation of bare-metal stents extended late-phase observation by intracoronary optical coherence tomography. J Am Coll Cardiol Dec 29(1):26\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2009.08.032","journal-title":"J Am Coll Cardiol Dec"},{"issue":"7","key":"3472_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/CIRCULATIONAHA.115.019071","volume":"16","author":"M Taniwaki","year":"2016","unstructured":"Taniwaki M, Radu MD, Zaugg S, Amabile N, Garcia-Garcia HM et al (2016) Mechanisms of very late Drug-Eluting stent thrombosis assessed by optical coherence tomography. Circulation Feb 16(7):650\u2013660. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.019071","journal-title":"Circulation Feb"},{"key":"3472_CR7","doi-asserted-by":"publisher","unstructured":"Nakamura D, Attizzani GF, Toma C, Sheth T, Wang W et al (2016) Failure mechanisms and neoatherosclerosis patterns in very late Drug-Eluting and Bare-Metal stent thrombosis. Circ Cardiovasc Interv Sep 9(9). https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.116.003785","DOI":"10.1161\/CIRCINTERVENTIONS.116.003785"},{"issue":"4","key":"3472_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.iccl.2022.02.005","volume":"11","author":"K Kawai","year":"2022","unstructured":"Kawai K, Virmani R, Finn AV (2022) In-Stent restenosis. Interv Cardiol Clin Oct 11(4):429\u2013443. https:\/\/doi.org\/10.1016\/j.iccl.2022.02.005","journal-title":"Interv Cardiol Clin Oct"},{"issue":"11","key":"3472_CR9","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/CIRCULATIONAHA.107.762047","volume":"9","author":"G Nakazawa","year":"2008","unstructured":"Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R et al (2008) Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation Sep 9(11):1138\u20131145. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.762047","journal-title":"Circulation Sep"},{"key":"3472_CR10","doi-asserted-by":"publisher","unstructured":"Kuroda M, Otake H, Shinke T, Takaya T, Nakagawa M et al (2016) The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. EuroIntervention. Dec 10.;12(11):e1366-e1374. https:\/\/doi.org\/10.4244\/EIJY15M12_05","DOI":"10.4244\/EIJY15M12_05"},{"issue":"9","key":"3472_CR11","doi-asserted-by":"publisher","first-page":"e011693","DOI":"10.1161\/CIRCINTERVENTIONS.121.011693","volume":"15","author":"Z Chen","year":"2022","unstructured":"Chen Z, Matsumura M, Mintz GS, Noguchi M, Fujimura T et al (2022) Prevalence and impact of neoatherosclerosis on clinical outcomes after percutaneous treatment of Second-Generation Drug-Eluting stent restenosis. Circ Cardiovasc Interv Sep 15(9):e011693. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.121.011693","journal-title":"Circ Cardiovasc Interv Sep"},{"issue":"1","key":"3472_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/MCA.0000000000000945","volume":"32","author":"H Shimono","year":"2021","unstructured":"Shimono H, Kajiya T, Takaoka J, Miyamura A, Inoue T et al (2021) Characteristics of recurrent in-stent restenosis after second- and third-generation drug-eluting stent implantation. Coron Artery Dis Jan 32(1):36\u201341. https:\/\/doi.org\/10.1097\/MCA.0000000000000945","journal-title":"Coron Artery Dis Jan"},{"issue":"22","key":"3472_CR13","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"29","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA et al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med Nov 29(22):2097\u20132107. https:\/\/doi.org\/10.1056\/NEJMoa1801174","journal-title":"N Engl J Med Nov"},{"issue":"18","key":"3472_CR14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"10","author":"L Raber","year":"2022","unstructured":"Raber L, Ueki Y, Otsuka T, Losdat S, Haner JD et al (2022) Effect of Alirocumab added to High-Intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA May 10(18):1771\u20131781. https:\/\/doi.org\/10.1001\/jama.2022.5218","journal-title":"JAMA May"},{"key":"3472_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ahj.2021.04.006","volume":"238","author":"C Zanchin","year":"2021","unstructured":"Zanchin C, Koskinas KC, Ueki Y, Losdat S, Haner JD et al (2021) Effects of the PCSK9 antibody Alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial. Am Heart J Aug 238:33\u201344. https:\/\/doi.org\/10.1016\/j.ahj.2021.04.006","journal-title":"Am Heart J Aug"},{"issue":"38","key":"3472_CR16","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"12","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C et al (2023) 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J Oct 12(38):3720\u20133826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191","journal-title":"Eur Heart J Oct"},{"issue":"26","key":"3472_CR17","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1093\/eurheartj\/ehy273","volume":"7","author":"G Guagliumi","year":"2018","unstructured":"Guagliumi G, Shimamura K, Sirbu V, Garbo R, Boccuzzi G et al (2018) Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. Eur Heart J Jul 7(26):2448\u20132456. https:\/\/doi.org\/10.1093\/eurheartj\/ehy273","journal-title":"Eur Heart J Jul"},{"issue":"12","key":"3472_CR18","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jacc.2011.09.079","volume":"20","author":"GJ Tearney","year":"2012","unstructured":"Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P et al (2012) Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the international working group for intravascular optical coherence tomography standardization and validation. J Am Coll Cardiol Mar 20(12):1058\u20131072. https:\/\/doi.org\/10.1016\/j.jacc.2011.09.079","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3472_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jjcc.2019.01.002","volume":"74","author":"M Hoshino","year":"2019","unstructured":"Hoshino M, Yonetsu T, Kanaji Y, Usui E, Yamaguchi M et al (2019) Impact of baseline plaque characteristic on the development of neoatherosclerosis in the very late phase after stenting. J Cardiol Jul 74(1):67\u201373. https:\/\/doi.org\/10.1016\/j.jjcc.2019.01.002","journal-title":"J Cardiol Jul"},{"issue":"9","key":"3472_CR20","doi-asserted-by":"publisher","first-page":"e011975","DOI":"10.1161\/JAHA.119.011975","volume":"7","author":"Y Nagano","year":"2019","unstructured":"Nagano Y, Otake H, Toba T, Kuroda K, Shinkura Y et al (2019) Impaired Cholesterol-Uptake capacity of HDL might promote Target-Lesion revascularization by inducing neoatherosclerosis after stent implantation. J Am Heart Assoc May 7(9):e011975. https:\/\/doi.org\/10.1161\/JAHA.119.011975","journal-title":"J Am Heart Assoc"},{"key":"3472_CR21","doi-asserted-by":"crossref","unstructured":"Kakizaki R, H\u00e4ner J, Taniwaki M, Ohno Y, Yahagi K, THE IMPACT OF ACHIEVING GUIDELINE-ENDORSED LDL CHOLESTEROL LEVELS ON NEOATHEROSCLEROSIS FORMATION IN PATIENTS WITH STEMI (2025) : A SUBSTUDY OF THE RANDOMIZED CONNECT TRIAL. Presented at: American Control Conference 74th Annual Scientific Session; March ; Chicago, IL","DOI":"10.1016\/S0735-1097(25)01305-1"},{"issue":"8","key":"3472_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/ehjci\/jeu035","volume":"15","author":"G Niccoli","year":"2014","unstructured":"Niccoli G, Dato I, Imaeva AE, Antonazzo Panico R, Roberto M et al (2014) Association between inflammatory biomarkers and in-stent restenosis tissue features: an optical coherence tomography study. Eur Heart J Cardiovasc Imaging Aug 15(8):917\u2013925. https:\/\/doi.org\/10.1093\/ehjci\/jeu035","journal-title":"Eur Heart J Cardiovasc Imaging Aug"},{"issue":"9","key":"3472_CR23","doi-asserted-by":"publisher","first-page":"e022348","DOI":"10.1136\/bmjopen-2018-022348","volume":"4","author":"YX Cao","year":"2018","unstructured":"Cao YX, Li S, Liu HH, Li JJ (2018) Impact of PCSK9 monoclonal antibodies on Circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials. BMJ Open Oct 4(9):e022348. https:\/\/doi.org\/10.1136\/bmjopen-2018-022348","journal-title":"BMJ Open Oct"},{"issue":"32","key":"3472_CR24","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1093\/eurheartj\/ehv227","volume":"21","author":"M Taniwaki","year":"2015","unstructured":"Taniwaki M, Windecker S, Zaugg S, Stefanini GG, Baumgartner S et al (2015) The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J Aug 21(32):2167\u20132176. https:\/\/doi.org\/10.1093\/eurheartj\/ehv227","journal-title":"Eur Heart J Aug"},{"issue":"2","key":"3472_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jacl.2023.01.004","volume":"17","author":"R Sakai","year":"2023","unstructured":"Sakai R, Sekimoto T, Koba S, Mori H, Matsukawa N et al (2023) Impact of triglyceride-rich lipoproteins on early in-stent neoatherosclerosis formation in patients undergoing Statin treatment. J Clin Lipidol Mar-Apr 17(2):281\u2013290. https:\/\/doi.org\/10.1016\/j.jacl.2023.01.004","journal-title":"J Clin Lipidol Mar-Apr"},{"key":"3472_CR26","doi-asserted-by":"publisher","unstructured":"Taniwaki M, Haner JD, Kakizaki R, Ohno Y, Yahagi K et al (2024) Long-term effect of biodegradable vs durable polymer everolimus-eluting stents on neoatherosclerosis in ST-segment elevation myocardial infarction: the CONNECT trial. Eur Heart J Sep 1. https:\/\/doi.org\/10.1093\/eurheartj\/ehae589","DOI":"10.1093\/eurheartj\/ehae589"},{"issue":"2","key":"3472_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.atherosclerosis.2015.08.014","volume":"242","author":"JY Jang","year":"2015","unstructured":"Jang JY, Kim JS, Shin DH, Kim BK, Ko YG et al (2015) Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis. Atherosclerosis Oct 242(2):553\u2013559. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.08.014","journal-title":"Atherosclerosis Oct"},{"issue":"6","key":"3472_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4244\/EIJ-D-20-00539","volume":"27","author":"D Nakamura","year":"2021","unstructured":"Nakamura D, Dohi T, Ishihara T, Kikuchi A, Mori N et al (2021) Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis. EuroIntervention Aug 27(6):489\u2013496. https:\/\/doi.org\/10.4244\/EIJ-D-20-00539","journal-title":"EuroIntervention Aug"},{"issue":"2","key":"3472_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10554-022-02736-3","volume":"39","author":"X Yuan","year":"2023","unstructured":"Yuan X, Han Y, Hu X, Jiang M, Feng H et al (2023) Lipoprotein (a) is related to In-Stent neoatherosclerosis incidence rate and plaque vulnerability: optical coherence tomography study. Int J Cardiovasc Imaging Feb 39(2):275\u2013284. https:\/\/doi.org\/10.1007\/s10554-022-02736-3","journal-title":"Int J Cardiovasc Imaging Feb"},{"issue":"3","key":"3472_CR30","doi-asserted-by":"publisher","first-page":"e011382","DOI":"10.1161\/CIRCINTERVENTIONS.121.011382","volume":"15","author":"RHM Furtado","year":"2022","unstructured":"Furtado RHM, Fagundes AA Jr., Oyama K, Zelniker TA, Tang M et al (2022) Effect of Evolocumab in patients with prior percutaneous coronary intervention. Circ Cardiovasc Interv Mar 15(3):e011382. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.121.011382","journal-title":"Circ Cardiovasc Interv Mar"},{"issue":"7","key":"3472_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.amjcard.2012.05.027","volume":"1","author":"T Yonetsu","year":"2012","unstructured":"Yonetsu T, Kim JS, Kato K, Kim SJ, Xing L et al (2012) Comparison of incidence and time course of neoatherosclerosis between bare metal stents and drug-eluting stents using optical coherence tomography. Am J Cardiol Oct 1(7):933\u2013939. https:\/\/doi.org\/10.1016\/j.amjcard.2012.05.027","journal-title":"Am J Cardiol"},{"issue":"8","key":"3472_CR32","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s10554-017-1106-2","volume":"33","author":"L Song","year":"2017","unstructured":"Song L, Mintz GS, Yin D, Yamamoto MH, Chin CY et al (2017) Neoatherosclerosis assessed with optical coherence tomography in restenotic bare metal and first- and second-generation drug-eluting stents. Int J Cardiovasc Imaging Aug 33(8):1115\u20131124. https:\/\/doi.org\/10.1007\/s10554-017-1106-2","journal-title":"Int J Cardiovasc Imaging Aug"},{"issue":"2","key":"3472_CR33","doi-asserted-by":"publisher","first-page":"e001878","DOI":"10.1161\/CIRCINTERVENTIONS.114.001878","volume":"8","author":"SY Lee","year":"2015","unstructured":"Lee SY, Hur SH, Lee SG, Kim SW, Shin DH et al (2015) Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation. Circ Cardiovasc Interv Feb 8(2):e001878. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.114.001878","journal-title":"Circ Cardiovasc Interv Feb"},{"issue":"5","key":"3472_CR34","doi-asserted-by":"publisher","first-page":"e008869","DOI":"10.1161\/CIRCINTERVENTIONS.119.008869","volume":"13","author":"H Jinnouchi","year":"2020","unstructured":"Jinnouchi H, Otsuka F, Sato Y, Bhoite RR, Sakamoto A et al (2020) Healthy strut coverage after coronary stent implantation: an ex vivo human autopsy study. Circ Cardiovasc Interv May 13(5):e008869. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.008869","journal-title":"Circ Cardiovasc Interv May"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-025-03472-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10554-025-03472-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-025-03472-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T01:03:08Z","timestamp":1756861388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10554-025-03472-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["3472"],"URL":"https:\/\/doi.org\/10.1007\/s10554-025-03472-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6592491\/v1","asserted-by":"object"}]},"ISSN":["1875-8312"],"issn-type":[{"value":"1875-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kakizaki reported receiving consulting fee from Infraredx USA, speaker fee from Abbott Medical Japan, Boston Scientific Japan, Philips Japan, Orbusneich Medical, manuscript writing fee from Orbusneich Medical and Philips Japan, Support for attending meetings and travel from OM Pharma outside the submitted work. Dr. Ueki reported receiving grants from Astellas Pharma, personal fees from Abbott Vascular, Amgen, Bayer, Daiichi Sankyo, Kowa, NIPRO, and Novartis, outside the submitted work. Dr. Koskinas reported receiving grants from Sanofi, Regeneron, and Infraredx during the conduct of the study and personal fees from Amgen and Daiichi Sankyo outside the submitted work. No other disclosures were reported. Dr. Losdat is employed by the DCR Bern, University of Bern, which has a staff policy of not accepting honoraria or consultancy fees. However, CTU Bern is involved in design, conduct, or analysis of clinical studies funded by not-for-profit and for-profit organizations. In particular, pharmaceutical and medical device companies provide direct funding to some of these studies. (for an up-to-date list of DCR Bern\u2019s conflicts of interest, see\n                      \n                      ) Dr. Biccir\u00e8 reported receiving consulting fee from Abbott, speaker fee from Abbott, Ultragenyx, and Sanofi outside the submitted work. Dr. Otsuka reported receiving speaker fees from Amgen, Nipro, and Kowa. Dr. L\u00f8nborg reported receiving grants from Boston Scientific, consulting fees from Boston Scientific, speakers fee from Abbott and Boston Scientific, and Support for attending meetings and travel from Abbott, and owns stock in Novo Nordisk. Dr. Kaiser reported receiving consulting fees from Unimedtec Switzerland and Swiss office of federal health. Dr. Iglesias reported receiving grants from Biotronik, Concept Medical, and Terumo, consulting fees from Medtronic, Biotronik, Cordis, and ReCor Medical, speakers fees from Medtronic, Penumbra, Biotronik, Concept Medical, BRISTOL MYERS SQUIBB\/PFIZER, Cordis, and Recor Medical, Support for attending meetings and travel from Biotronik, and participating Data Safety Monitoring Board of the CoSTAR trial (NCT04870424). Dr. Spirk reported receiving personal fees from Sanofi-Aventis (Switzerland) at the time of study conduct and Cook Medical outside the submitted work. Dr. Daemen reported receiving institutional grant\/research support from Abbott Vascular, Boston Scientific, ACIST Medical, Medtronic, Pie Medical, and ReCor medical, and consultancy and speaker fees from Abbott Vascular, Abiomed, ACIST medical, Boston Scientific, Cardialysis BV, CardiacBooster, Kaminari Medical, ReCor Medical, PulseCath, Pie Medical, Sanofi, Siemens Health Care and Medtronic. Dr Engstr\u00f8m reported advisory board fees from Abbott and Novo Nordisk and speaker fees from Boston Scientific outside the submitted work. Dr. Lang has relationships with drug companies including AOP-Health, Actelion-Janssen, MSD, United Therapeutics, Pulnovo, Medtronic, INARI, Neutrolis and Sanofi. In addition to being investigator in trials involving these companies, relationships include consultancy service, research grants, and membership of scientific advisory boards. Dr. R\u00e4ber reported receiving grants from Sanofi, Regeneron, and Infraredx to Inselspital and speaker fees from Sanofi during the conduct of the study and grants from Abbott, Heartflow, Boston Scientific, and Biotronik to Inselspital and grants from Abbott, Amgen, AstraZeneca, Occlutech, Sanofi, Canon, and Medtronic for speaker and consultation fees outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki, and the study was approved by the ethical committee at each site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study, all patients provided written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided informed consent, acknowledging that their health-related and personal information (and samples) would be shared only in encrypted form for research purposes, including international collaboration, and that their names would not be published in any form.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}